Summit Trail Advisors’s Abiomed Inc ABMD Stock Holding History

Summit Trail Advisors’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-27	Closed	-$6K	–	1814
2017 Q4	$6K	Buy	+27	New	+$5.04K	﹤0.01%	1382

Other funds holding ABMD

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Winslow Capital Management Minneapolis, Minnesota $25.6B AUM 33.75% 1-Year Est. Return

Summit Trail Advisors's ABMD Position: Q1 2018 in Review

Summit Trail Advisors sold out of Abiomed Inc (ABMD) in Q1 2018, closing a stake of 27 shares — an estimated $6K sold.

Summit Trail Advisors first reported a position in ABMD in Q4 2017 and held it in 1 quarter. The position peaked at $6K in Q4 2017. 405 funds tracked by Wall St. Rank hold ABMD as of Q1 2018.

Summit Trail Advisors reported no remaining Abiomed Inc position as of Q1 2018 after selling out during the quarter.
Summit Trail Advisors sold 27 Abiomed Inc shares in Q1 2018, an estimated $6K.
Summit Trail Advisors first reported a position in Abiomed Inc in Q4 2017 and held it in 1 quarter.
Summit Trail Advisors's Abiomed Inc position peaked at $6K in Q4 2017.
405 funds tracked by Wall St. Rank held Abiomed Inc as of Q1 2018.

Based on Summit Trail Advisors's 13F filing for Q1 2018, filed 21 May 2018.